Innoviva Inc  

(Public, NASDAQ:INVA)   Watch this stock  
Find more results for NASDAQ:THRX
11.49
-0.01 (-0.09%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.41 - 11.70
52 week 6.36 - 16.81
Open 11.51
Vol / Avg. 506,902.00/684,269.00
Mkt cap 1.30B
P/E     -
Div/yield 0.25/8.70
EPS -0.03
Shares 113.00M
Beta 1.65
Inst. own 84%
Jul 28, 2016
Q2 2016 Innoviva Inc Earnings Call - 5:00PM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Innoviva Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 10, 2016
Innoviva Inc at Jefferies Healthcare Conference
May 11, 2016
Innoviva Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
Apr 28, 2016
Q1 2016 Innoviva Inc Earnings Call
Apr 28, 2016
Q1 2016 Innoviva Inc Earnings Release
Apr 26, 2016
Innoviva Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 18.34% -34.77%
Operating margin 72.52% 58.54%
EBITD margin - 84.36%
Return on average assets 4.47% -4.03%
Return on average equity - -
Employees 13 -
CDP Score - -

Address

951 Gateway Blvd
SOUTH SAN FRANCISCO, CA 94080-7024
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

Officers and directors

William H. Waltrip Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Michael E. Faerm Senior Vice President and Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Age: 58
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Catherine J. Friedman Independent Director
Age: 55
Bio & Compensation  - Reuters
Terrence C. Kearney Independent Director
Age: 61
Bio & Compensation  - Reuters
Paul Pepe Independent Director
Age: 56
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters